Our | Products


PONATIB





THERAPEUTIC AREA: Oncology / Hematology + Onco-Hematology
ACTIVE PRINCIPLE: Ponatinib
PRESENTATION: 15 and 45 mg coated tablets
INDICATION:

  • Acute Lymphoblastic Leukemia
  • Chronic Myeloid Leukemia

COUNTRIES WHERE IT IS MARKETED:
Argentina